PlantForm and PharmaPraxis Establish Joint Biosimilar Development Venture - - BioPharm International

ADVERTISEMENT

PlantForm and PharmaPraxis Establish Joint Biosimilar Development Venture


PlantForm and PharmaPraxis announce plans to developm six biopharmaceutical targets for the Brazilian market.

PlantForm Corporation of Canada and PharmaPraxis of Brazil have announced a joint venture to develop, manufacture and commercialize biosimilar and/or biobetter versions of six biopharmaceuticals for the Brazilian market, using PlantForm’s manufacturing system.

The joint venture will first develop a biosimilar/biobetter version of the oncology drug Avastin (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology in Newark, Del., which will produce the active pharmaceutical ingredient (API) for clinical trials.

Brazilian government corporation Bio-Manguinhos will also participate in the project. Bio-Manguinhos is responsible for technology development and production of vaccines, reagents and biopharmaceuticals to meet public health demands.

The joint venture will build a pilot cGMP biopharmaceutical manufacturing facility in Brazil.

Source: PlantForm

 

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Merck KGaA Announces Acquisition of Sigma-Aldrich for $17 Billion
September 22, 2014
Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Author Guidelines

Click here